CLSN Key Statistics, Chart & Performance
The current stock price of CLSN is 1.96 USD. In the past month the price decreased by -15.52%. In the past year, price decreased by -87.06%.
CLSN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.26 | 405.26B | ||
| AMGN | AMGEN INC | 14.94 | 175.88B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 150.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.96 | 114.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.2 | 81.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.39 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.15B | ||
| NTRA | NATERA INC | N/A | 31.36B | ||
| BIIB | BIOGEN INC | 10.51 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.65 | 21.19B | ||
| INCY | INCYTE CORP | 15.65 | 19.73B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About CLSN
Company Profile
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Company Info
CELSION CORP
997 Lenox Dr Ste 100
Lawrence Township NEW JERSEY 08648 US
CEO: Michael H. Tardugno
Employees: 29
Phone: 16098969100.0
CELSION CORP / CLSN FAQ
What does CLSN do?
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Can you provide the latest stock price for CELSION CORP?
The current stock price of CLSN is 1.96 USD.
Does CLSN stock pay dividends?
CLSN does not pay a dividend.
How is the ChartMill rating for CELSION CORP?
CLSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
When does CELSION CORP (CLSN) report earnings?
CELSION CORP (CLSN) will report earnings on 2022-11-14.
Can you provide the ownership details for CLSN stock?
You can find the ownership structure of CELSION CORP (CLSN) on the Ownership tab.
CLSN Technical Analysis
CLSN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSN. Both the profitability and financial health of CLSN have multiple concerns.
CLSN Financial Highlights
Over the last trailing twelve months CLSN reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS decreased by -35.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5229.82% | ||
| ROA | -40.03% | ||
| ROE | N/A | ||
| Debt/Equity | 0.13 |
CLSN Forecast & Estimates
8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96.